Your IDE Approval Does Not Validate Your PMA Clinical Endpoint — Here's What Does

June 01, 2026

Key Takeaways

• FDA approves an IDE based on whether a study is safe and scientifically sound enough to proceed, but not as a pre-endorsement of your primary endpoint, statistical approach, or PMA evidence standard.

• The PMA reasonable assurance standard under 21 CFR 860.7 is a different and higher bar than IDE approvability, and failing to distinguish between the two is one of the most consequential planning errors we see in early-stage Class III programs.

• Use the Pre-Submission process to reach explicit agreement with FDA on your primary endpoint, statistical analysis plan, and evidence threshold before study startup.

Receiving IDE approval feels like a meaningful regulatory milestone — and it is. It means FDA reviewed your proposed study and found it safe and scientifically sufficient to proceed. For an early-stage company that has worked through protocol development, an investigational plan, and the full IDE application process, that approval is hard-won.

The mistake is treating it as more than that.

IDE Approval and PMA Approval Are Evaluated Against Different Standards

The IDE approval standard and the PMA approval standard are not the same. Understanding the distinction is not a regulatory technicality. It is foundational to your clinical development strategy.

Under 21 CFR Part 812, FDA approves an IDE when the proposed investigation does not present an unreasonable risk to human subjects and the protocol is scientifically sound enough to evaluate safety and effectiveness. That is the bar. FDA is asking: is this study appropriate to conduct?

The PMA standard is different. Under 21 CFR 860.7, FDA must find reasonable assurance that the device is safe and effective — based on valid scientific evidence sufficient to determine that the probable benefits of the device outweigh the probable risks. The agency is asking: has this device been proven?

Those are different questions. The practical implication here is significant: a study design that satisfies the IDE standard may still produce data that fails to satisfy the PMA standard, even when the study is executed perfectly.

FDA typically provides this feedback during IDE reviews through Study Design Considerations, which you should ensure your study design takes these into consideration to improve your chances of having clinical data that rises to the safety and effectiveness requirements for a PMA.

What IDE Approval Does Not Do

IDE approval does not:

• Confirm that your primary endpoint will be acceptable for PMA review

• Validate your statistical analysis plan or the specific success threshold you have defined

• Bind FDA to any particular evidentiary standard at the time of PMA review

Why Pre-Submission Alignment Before Study Startup Is Not Optional

The Q-Submission Program, governed by FDA's guidance Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program, exists precisely to resolve these questions before you are locked into a study design. A Pre-Submission (Q-Sub) filed before pivotal trial startup is the mechanism through which sponsors obtain FDA's agreement on the specific questions that will govern PMA review.

That means: your proposed primary endpoint. Your statistical analysis plan, including the null and alternative hypotheses, success threshold, and analytical approach. The follow-up period FDA considers clinically sufficient. Whether a composite endpoint will be treated as primary. How FDA expects you to handle missing data.

These are not questions to answer internally and assume FDA will accept. They are questions to bring to FDA directly, with enough lead time to redesign the study if the feedback requires it.

An important caveat: FDA's Q-Sub feedback is not binding, and FDA can and does evolve its thinking between Pre-Submission and PMA review.

Protecting Your Program Through Active Engagement

Companies that run the strongest pivotal trials do not just execute their protocol well. They maintain active regulatory engagement throughout the trial lifecycle. Three practices make a material difference:

Get Pre-Submission agreement before you start. File a Q-Sub before IDE submission or, at minimum, before site activation. Ask FDA directly about your primary endpoint, statistical plan, and the evidence threshold they consider sufficient. Receive that feedback in writing. Build your trial around it.

Treat Study Design Considerations as a to-do list. When FDA raises study design concerns during IDE review, those observations are not advisory. Address them formally and directly. If you disagree with a consideration, retain records documenting this discussion and resolution.

Revisit alignment after major protocol amendments. Endpoint changes, follow-up modifications, and responder definition revisions made mid-study without FDA input are among the most common sources of PMA clinical deficiencies. If your protocol changes materially through an IDE Supplement, you may also want to consider filing a Q-Sub.

Questions to Ask About Your Program

• Have you filed a Pre-Submission specifically to obtain FDA agreement on your primary endpoint and statistical analysis plan — separate from the IDE review process?

• Can you identify, by name and date, the FDA feedback that validates the evidence standard your PMA will be built around?

• If FDA raised Study Design Considerations during your IDE review, have you addressed each one in writing and documented FDA's response?

• Has your protocol been amended since IDE approval? If so, did FDA provide additional input in your IDE Supplement on how those changes affect your PMA evidence package? Have these been proactively addressed?

If any of these questions do not have a clear answer, your clinical strategy has a gap worth addressing before you begin enrollment.

If you are planning a pivotal trial and want a strategic perspective on your clinical evidence plan before you start, reach out to FCG.